Market Price

233.50 

-0.12 -0.1%

as of Jul 16 '19

52 Week Range:

216.12 388.67


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 20.16
22.64
22.44
25.73
29.43
34.38
44.46
48.37
56.13
60.81
69.81
growth rate 12.3% -0.9% 14.7% 14.4% 16.8% 29.3% 8.8% 16.0% 8.3% 14.8%
Earnings BIT 1,150.00
1,330.00
1,230.00
1,710.00
1,860.00
2,480.00
3,967.70
5,014.90
5,708.80
5,904.80
6,375.00
growth rate 15.7% -7.5% 39.0% 8.8% 33.3% 60.0% 26.4% 13.8% 3.4% 8.0%
Avg.PE 17.99
15.97
17.01
21.83
25.45
35.71
32.50
17.20
16.23
28.84
15.33
growth rate -11.2% 6.5% 28.3% 16.6% 40.3% -9.0% -47.1% -5.6% 77.7% -46.8%
ROA 9.16
11.39
12.08
14.40
14.39
16.94
22.42
20.97
17.47
10.91
18.11
growth rate 24.3% 6.1% 19.2% -0.1% 17.7% 32.4% -6.5% -16.7% -37.6% 66.0%
ROE 13.81
16.13
17.31
20.88
20.62
23.90
30.21
35.15
34.42
20.52
34.54
growth rate 16.8% 7.3% 20.6% -1.3% 15.9% 26.4% 16.4% -2.1% -40.4% 68.3%
ROIC 10.98
13.49
14.59
17.67
17.77
21.71
28.60
26.40
22.28
14.13
23.97
growth rate 22.9% 8.2% 21.1% 0.6% 22.2% 31.7% -7.7% -15.6% -36.6% 69.6%
Cur. Ratio 2.66
3.47
2.42
3.26
1.96
1.81
2.11
2.60
2.55
2.34
2.32
growth rate 30.5% -30.3% 34.7% -39.9% -7.7% 16.6% 23.2% -1.9% -8.2% -0.9%
Quick Ratio 2.19
2.81
1.95
2.74
1.61
1.31
1.54
1.93
1.94
1.78
1.83
growth rate 28.3% -30.6% 40.5% -41.2% -18.6% 17.6% 25.3% 0.5% -8.3% 2.8%
Leverage 1.46
1.37
1.50
1.41
1.46
1.38
1.32
2.08
1.88
1.88
1.94
growth rate -6.2% 9.5% -6.0% 3.6% -5.5% -4.4% 57.6% -9.6% 0.0% 3.2%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 446.70
551.20
605.30
813.33
955.24
1,077.07
1,575.80
1,541.50
1,742.20
2,319.60
2,485.40
growth rate 23.4% 9.8% 34.4% 17.5% 12.8% 46.3% -2.2% 13.0% 33.1% 7.2%
Acct.Payable 909.60
1,204.01
1,754.79
229.20
267.40
279.80
395.50
370.50
growth rate 32.4% 45.8% -86.9% 16.7% 4.6% 41.4% -6.3%
Cur.Assets 2,458.00
2,480.60
2,540.40
2,975.43
3,244.34
3,184.93
4,535.00
6,700.30
8,732.20
7,873.30
7,640.90
growth rate 0.9% 2.4% 17.1% 9.0% -1.8% 42.4% 47.8% 30.3% -9.8% -3.0%
Total Assets 8,479.00
8,551.90
8,092.50
9,049.60
10,130.12
11,863.34
14,314.70
19,504.80
22,876.80
23,652.60
25,288.90
growth rate 0.9% -5.4% 11.8% 11.9% 17.1% 20.7% 36.3% 17.3% 3.4% 6.9%
Cash 622.40
581.90
759.60
514.54
570.72
602.56
1,204.90
1,308.00
2,326.50
1,573.80
1,224.60
growth rate -6.5% 30.5% -32.3% 10.9% 5.6% 100.0% 8.6% 77.9% -32.4% -22.2%
Inventory 263.60
294.00
289.10
326.84
447.37
659.00
804.00
893.40
1,001.60
902.70
929.90
growth rate 11.5% -1.7% 13.1% 36.9% 47.3% 22.0% 11.1% 12.1% -9.9% 3.0%
Cur.Liabilities 923.20
714.90
1,050.10
912.89
1,657.39
1,758.28
2,218.10
2,577.70
3,419.90
3,368.20
3,295.20
growth rate -22.6% 46.9% -13.1% 81.6% 6.1% 26.2% 16.2% 32.7% -1.5% -2.2%
Liabilities 2,672.90
2,330.30
2,696.00
2,624.11
3,168.60
3,243.09
3,500.70
10,129.90
10,748.20
11,054.50
12,257.30
growth rate -12.8% 15.7% -2.7% 20.8% 2.4% 7.9% 189.4% 6.1% 2.9% 10.9%
LT Debt 1,085.40
1,080.20
1,066.40
1,060.81
687.40
592.43
580.30
6,521.50
6,512.70
5,935.00
5,936.50
growth rate -0.5% -1.3% -0.5% -35.2% -13.8% -2.1% 1,023.8% -0.1% -8.9% 0.0%
Equity 5,806.10
6,221.50
5,396.50
6,425.50
6,961.52
8,620.24
10,809.00
9,372.80
12,140.10
12,612.80
13,039.60
growth rate 7.2% -13.3% 19.1% 8.3% 23.8% 25.4% -13.3% 29.5% 3.9% 3.4%
Common Shares 295.00
289.00
255.00
245.00
240.00
238.00
237.00
231.00
219.00
213.00
205.00
growth rate -2.0% -11.8% -3.9% -2.0% -0.8% -0.4% -2.5% -5.2% -2.7% -3.8%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 276.00
165.60
173.10
208.02
254.55
246.30
287.80
643.00
616.10
867.40
770.60
growth rate -40.0% 4.5% 20.2% 22.4% -3.2% 16.9% 123.4% -4.2% 40.8% -11.2%
Cash Dividends 0.00
0.00
23.50
27.10
0.00
0.00
56.10
134.10
134.10
growth rate 15.3% -100.0% 139.0% 0.0%
Cash From OA 1,562.40
1,074.90
1,624.70
1,727.74
1,879.90
2,345.10
2,942.10
3,919.40
4,587.20
4,551.00
6,187.70
growth rate -31.2% 51.2% 6.3% 8.8% 24.8% 25.5% 33.2% 17.0% -0.8% 36.0%
FCF per Share 4.37
3.14
5.70
5.95
6.75
-6.38
11.03
12.95
14.85
12.60
23.31
growth rate -28.2% 81.5% 4.4% 13.5% -100.0% 100.0% 17.4% 14.7% -15.2% 85.0%
Sale Purchase of Stock -331.59
-917.22
-333.50
54.90
-5,000.00
-1,000.00
-1,668.10
growth rate 0.0% 0.0% 100.0% -100.0% 0.0% 0.0%
FCF 1,289.00
909.00
1,452.00
1,476.00
1,619.00
-1,164.00
2,654.00
3,073.00
3,794.00
2,588.00
5,302.00
growth rate -29.5% 59.7% 1.7% 9.7% -100.0% 100.0% 15.8% 23.5% -31.8% 104.9%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 4,097.50
4,377.30
4,716.40
5,048.63
5,516.46
6,932.20
9,703.30
10,763.80
11,448.80
12,273.90
13,452.90
growth rate 6.8% 7.8% 7.0% 9.3% 25.7% 40.0% 10.9% 6.4% 7.2% 9.6%
Op.Income 1,213.60
1,295.40
1,248.90
1,234.43
1,426.83
1,887.30
3,967.70
5,014.90
5,708.80
5,904.80
6,375.00
growth rate 6.7% -3.6% -1.2% 15.6% 32.3% 110.2% 26.4% 13.8% 3.4% 8.0%
IBT 1,155.90
1,332.70
1,229.90
1,711.21
1,901.90
2,505.50
3,931.50
4,754.80
4,933.00
5,128.80
5,899.60
growth rate 15.3% -7.7% 39.1% 11.1% 31.7% 56.9% 20.9% 3.8% 4.0% 15.0%
Net Income 783.20
970.10
1,005.30
1,234.43
1,426.83
1,887.30
2,934.80
3,547.00
3,702.80
2,539.10
4,430.70
growth rate 23.9% 3.6% 22.8% 15.6% 32.3% 55.5% 20.9% 4.4% -31.4% 74.5%
EPS 2.65
3.35
3.94
5.04
5.76
7.81
12.37
15.34
16.93
11.92
21.58
growth rate 26.4% 17.6% 27.9% 14.3% 35.6% 58.4% 24.0% 10.4% -29.6% 81.0%
Gross Profit 3,695.50
3,995.20
4,316.20
4,581.85
4,970.97
6,074.50
8,532.30
9,523.40
10,015.60
10,643.90
11,636.60
growth rate 8.1% 8.0% 6.2% 8.5% 22.2% 40.5% 11.6% 5.2% 6.3% 9.3%
R&D 1,072.10
1,283.10
1,248.60
1,219.60
1,334.92
1,444.10
1,893.40
2,012.80
1,973.30
2,253.60
2,597.20
growth rate 19.7% -2.7% -2.3% 9.5% 8.2% 31.1% 6.3% -2.0% 14.2% 15.3%

Quarterly Statements

Item Name Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Earnings BIT 1,540.70
1,291.70
1,832.50
1,710.10
1,630.10
growth rate -16.2% 41.9% -6.7% -4.7%
Balance Sheet Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Acct.Receivable 2,492.70
2,432.90
2,525.70
2,485.40
2,616.00
growth rate -2.4% 3.8% -1.6% 5.3%
Acct.Payable 345.80
295.70
342.30
370.50
378.00
growth rate -14.5% 15.8% 8.2% 2.0%
Cur.Assets 10,195.40
7,432.10
8,719.00
7,640.90
8,942.60
growth rate -27.1% 17.3% -12.4% 17.0%
Total Assets 26,090.10
23,952.90
25,492.20
25,288.90
26,445.50
growth rate -8.2% 6.4% -0.8% 4.6%
Cash 4,108.00
1,250.20
2,386.70
1,224.60
2,243.20
growth rate -69.6% 90.9% -48.7% 83.2%
Inventory 890.80
931.70
916.60
929.90
770.20
growth rate 4.6% -1.6% 1.5% -17.2%
Cur.Liabilities 3,152.10
3,152.40
3,174.90
3,295.20
3,148.70
growth rate 0.0% 0.7% 3.8% -4.5%
Liabilities 12,052.60
11,699.20
11,732.40
12,257.30
12,623.50
growth rate -2.9% 0.3% 4.5% 3.0%
LT Debt 5,929.40
5,928.40
5,931.10
5,936.50
6,379.30
growth rate 0.0% 0.1% 0.1% 7.5%
Equity 14,053.70
12,260.90
13,766.60
13,039.60
13,829.90
growth rate -12.8% 12.3% -5.3% 6.1%
Common Shares 0.10
0.10
0.10
0.10
0.10
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Capital Expenditures 194.70
186.80
163.20
225.90
127.10
growth rate -4.1% -12.6% 38.4% -43.7%
Cash Dividends
growth rate
Cash From OA 1,457.10
1,099.30
1,735.90
1,895.40
1,459.50
growth rate -24.6% 57.9% 9.2% -23.0%
Sale Purchase of Stock -250.00
growth rate
FCF 1,262.40
912.50
1,572.70
1,669.50
1,332.40
growth rate -27.7% 72.4% 6.2% -20.2%
Income Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Sales 3,131.10
3,356.50
3,439.00
3,526.30
3,489.80
growth rate 7.2% 2.5% 2.5% -1.0%
Op.Income 1,540.70
1,291.70
1,832.50
1,710.10
1,630.10
growth rate -16.2% 41.9% -6.7% -4.7%
IBT 1,493.70
1,178.70
1,812.70
1,414.50
1,831.30
growth rate -21.1% 53.8% -22.0% 29.5%
Net Income 1,172.90
866.60
1,444.40
946.80
1,408.80
growth rate -26.1% 66.7% -34.5% 48.8%
EPS
growth rate
Gross Profit 2,685.10
2,935.50
2,978.20
3,037.80
2,887.80
growth rate 9.3% 1.5% 2.0% -4.9%
R&D 496.70
981.00
507.90
611.60
563.40
growth rate 97.5% -48.2% 20.4% -7.9%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (90.95)

YOY Growth Grade:

C (64.94)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 9.96 10.09 7.51
EPS / Growth 27.5% 23.14 7.2%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 8.2%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 7.2% 7.7% 7.7%
Future PE 7.51 10.96 10.96
Future EPS 46.17 48.59 48.59
Value Price
MOS %
85.71
-63.3%
131.61
-43.6%
131.61
-43.6%
MOS Price 42.86 65.80 65.80
IRT 7.45 7.31 7.31

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.